<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311635</url>
  </required_header>
  <id_info>
    <org_study_id>D9830C00020</org_study_id>
    <nct_id>NCT01311635</nct_id>
  </id_info>
  <brief_title>A Bioavailability Study Comparing 3 Different AZD1981 Tablets</brief_title>
  <official_title>A Phase I, Open Label, Randomised, 4-way Crossover Study to Investigate the Relative Bioavailability of Single Dose AZD1981 Via 3 Different Tablets in Healthy Men and Healthy Women of Non-childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the relative bioavailability of AZD1981 when using a
      new tablet compared to the current tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the area under the plasma concentration time-curve from zero to infinity /AUC) and the maximum plasma concentration (Cmax) of AZD1981</measure>
    <time_frame>Pharmacokinetic (PK) sampling continuously for 60 h after each single dose, ie day 1-3 for each period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate basic systemic PK parameters as follows:</measure>
    <time_frame>PK sampling continuously for 60 h after each single dose, ie day 1-3 for each period</time_frame>
    <description>AUC(0-t): area under the plasma concentration versus time curve from time zero to time of last quantifiable concentration
tmax: time to reach Cmax
t1/2λz: terminal half-life
CL/F: apparent plasma clearance
MRT: apparent mean residence time
Vz/F: apparent volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of AZD1981 by assessment of adverse events, laboratory safety parameters, vital signs, ECG, physical examination and weight</measure>
    <time_frame>Safety will be monitored continuously and safety assessments will be made on several occasions throughout the whole study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981, current small-particle tablet</intervention_name>
    <description>3x100 mg per oral, single dose in fasted state</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981, new small-particle tablet</intervention_name>
    <description>3x100 mg per oral, single dose</description>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981, new large-particle table</intervention_name>
    <description>3x100 mg per oral, single dose in fasted state</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and postmenopausal or surgically sterile female volunteers aged 18-55,
             inclusive

          -  Have a body mass index between 19-30 kg/m2 and weigh at least 50 kg and no more than
             100 kg, inclusive

          -  Be a non-smoker or ex-smoker who has stopped smoking for &gt;6 months prior to screening

          -  Volunteers must be willing to use barrier methods of contraceptive, unless their
             partners are post-menopausal, surgically sterile or using accepted contraceptive
             methods.

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Any clinically relevant abnormal findings in the physical examination, clinical
             chemistry, haematology, urinalysis, vital signs (including body temperature), or ECG
             assessments at Visit 1, or in vital signs (including body temperature) at Visit 2

          -  Prolonged QTcF &gt;450 ms or shortened QTcF&lt;340 ms at Visit 1 or family history of long
             QT syndrome

          -  History of, or current alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Kühn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB, Phase 1 Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Christer Hultquist / MD</name_title>
    <organization>AstraZeneca R&amp;D</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>bioavailability study</keyword>
  <keyword>AZD1981</keyword>
  <keyword>tablets</keyword>
  <keyword>To study the relative bioavailability of single dose AZD1981 via three different tablets</keyword>
  <keyword>To compare the bioavailability between three different AZD1981 tablets</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

